Article Details
Retrieved on: 2025-03-31 11:29:25
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... immune system and selectively targeting disease-causing B cells. Product Pipeline: The company is advancing six RESETTM Phase 1/2 clinical trials ...
Article found on: www.tradingview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here